[EN] BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS<br/>[FR] COMPOSÉS BIARYLES UTILES EN TANT QU'IMMUNOMODULATEURS
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2018044963A1
公开(公告)日:2018-03-08
The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
The invention relates to a compound of formula (I)
wherein A and R
1
to R
3
are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
[EN] [1, 2, 3]TRIAZOLO [4, 5 -D] PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 AGONISTS<br/>[FR] DÉRIVÉS DE [1, 2, 3]TRIAZOLO [4, 5 -D] PYRIMIDINE COMME AGONISTES DES RÉCEPTEURS AUX CANNABINOÏDES 2
申请人:HOFFMANN LA ROCHE
公开号:WO2013076182A1
公开(公告)日:2013-05-30
The invention relates to a compound of formula (I) wherein A and R to R 3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
Compounds of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, and A are as described herein, are set forth. These compounds are useful as anti-allergic agents and agents for the treatment of cardiovascular diseases.
[EN] IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS<br/>[FR] DÉRIVÉS D'IMIDAZOLINE UTILISÉS EN TANT QUE MODULATEURS DE CXCR4
申请人:UNIV PARIS
公开号:WO2020201096A1
公开(公告)日:2020-10-08
The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as CXCR4 modulators that specifically target the CXCR4 minor pocket, and they have further been found to inhibit the production of inflammatory cytokines in immune cells, which renders these compounds highly advantageous for use in therapy, particularly in the treatment or prevention of an inflammatory disorder, an autoimmune disorder, an autoinflammatory disorder, or an interferonopathy, such as, e.g., lupus erythematosus, dermatomyositis or rheumatoid arthritis.